FY2026 Earnings Estimate for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Issued By Zacks Research

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at Zacks Research decreased their FY2026 EPS estimates for Sarepta Therapeutics in a report released on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of $10.13 per share for the year, down from their prior estimate of $11.48. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

A number of other equities research analysts have also recently commented on SRPT. UBS Group increased their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Citigroup raised their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. BMO Capital Markets initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target for the company. Mizuho raised their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, Barclays raised their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $156.60.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $128.77 on Thursday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The business has a 50-day moving average price of $126.11 and a 200 day moving average price of $110.47. The company has a market capitalization of $12.09 billion, a P/E ratio of -21.04 and a beta of 0.94. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.50. The firm had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period in the previous year, the company posted ($1.24) earnings per share.

Insider Activity at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 3,135 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the sale, the director now owns 6,621 shares in the company, valued at $814,118.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares in the company, valued at approximately $814,118.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently modified their holdings of SRPT. Principal Securities Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $26,000. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics in the first quarter worth about $28,000. Montag A & Associates Inc. purchased a new position in shares of Sarepta Therapeutics in the third quarter worth about $30,000. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.